{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:57:01Z","timestamp":1785369421395,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05613-5","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T03:38:24Z","timestamp":1745811504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Bacillus Calmette-Gu\u00e9rin compared to sequential gemcitabine and docetaxel in Ta high-grade non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-6058","authenticated-orcid":false,"given":"Ahmed","family":"Eraky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Hug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Ben-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik P.","family":"Kolanukuduru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Waingankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyrollis","family":"Attalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"5613_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.urolonc.2023.10.004","volume":"41","author":"J Bedke","year":"2023","unstructured":"Bedke J, Black PC, Szabados B, Guerrero-Ramos F, Shariat SF, Xylinas E et al (2023) Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: the evolving role of PD-(L)1 Inhibition. Urologic Oncology: Seminars Original Investigations 41:461\u2013475. https:\/\/doi.org\/10.1016\/j.urolonc.2023.10.004","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"5613_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on Non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in Situ). Eur Urol 81:75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"key":"5613_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC et al (2024) Diagnosis and treatment of Non-Muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol 211:533\u2013538. https:\/\/doi.org\/10.1097\/JU.0000000000003846","journal-title":"J Urol"},{"key":"5613_CR4","unstructured":"Gontero P (Chair), Birtle A, Comp\u00e9rat E, Dominguez Escrig JL, Liedberg F, Mariappan P, Masson-Lecomte A, Mostafid AH, van Rhijn BWG, Seisen T, Shariat SF, Xylinas EN, Patient Advocates: R. Wood et al (2024): n.d"},{"key":"5613_CR5","doi-asserted-by":"publisher","unstructured":"Liu Y, Lu J, Huang Y, Ma L Clinical spectrum of complications induced by intravesical immunotherapy of Bacillus Calmette-Gu\u00e9rin for bladder cancer. J Oncol 2019;2019:6230409. https:\/\/doi.org\/10.1155\/2019\/6230409","DOI":"10.1155\/2019\/6230409"},{"key":"5613_CR6","doi-asserted-by":"publisher","unstructured":"Steinberg RL, Thomas LJ, O\u2019Donnell MA, Nepple KG Sequential intravesical gemcitabine and docetaxel for the salvage treatment of Non-Muscle invasive bladder cancer. Bladder Cancer N D;1:65\u201372. https:\/\/doi.org\/10.3233\/BLC-150008","DOI":"10.3233\/BLC-150008"},{"key":"5613_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00345-024-04992-5","volume":"42","author":"R Ben-David","year":"2024","unstructured":"Ben-David R, Tillu N, Alerasool P, Bieber C, Ranti D, Tolani S et al (2024) Induction and maintenance of sequential intravesical Gemcitabine\/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols. World J Urol 42:315. https:\/\/doi.org\/10.1007\/s00345-024-04992-5","journal-title":"World J Urol"},{"key":"5613_CR8","doi-asserted-by":"publisher","unstructured":"McElree IM, Orzel J, Stubbee R, Steinberg RL, Mott SL, O\u2019Donnell MA et al (2023) Sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve and previously treated intermediate-risk nonmuscle invasive bladder cancer. Urol Oncol 41. https:\/\/doi.org\/10.1016\/j.urolonc.2023.06.017.:485.e1-485.e7","DOI":"10.1016\/j.urolonc.2023.06.017"},{"key":"5613_CR9","doi-asserted-by":"publisher","unstructured":"Kolanukuduru KP, Ben-David R, Lidagoster S, Almoflihi M, Tillu N, Eraky A et al Comparative effectiveness of Bacillus Calmette-Gu\u00e9rin and sequential intravesical gemcitabine and docetaxel for Treatment-na\u00efve Intermediate-risk Non-muscle-invasive bladder cancer. Eur Urol Focus 2024:S2405-4569(24)00173-1. https:\/\/doi.org\/10.1016\/j.euf.2024.09.006","DOI":"10.1016\/j.euf.2024.09.006"},{"key":"5613_CR10","doi-asserted-by":"publisher","unstructured":"Musat MG, Kwon CS, Masters E, Sikirica S, Pijush DB, Forsythe A. Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence(RWE) Studies: Systematic Literature Review (SLR). Clinicoecon Outcomes Res 2022;14:35\u201348.https:\/\/doi.org\/10.2147\/CEOR.S341896","DOI":"10.2147\/CEOR.S341896"},{"key":"5613_CR11","doi-asserted-by":"publisher","first-page":"40e17","DOI":"10.1016\/j.urolonc.2019.07.022","volume":"38","author":"MJ Daniels","year":"2020","unstructured":"Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ, Sankin A et al (2020) An evaluation of monthly maintenance therapy among patients receiving intravesical combination Gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer. Urologic Oncology: Seminars Original Investigations 38:40e17. 40.e24","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"5613_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in Intermediate- and High-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63:462\u2013472. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.039","journal-title":"Eur Urol"},{"key":"5613_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002740","author":"IM McElree","year":"2022","unstructured":"McElree IM, Steinberg RL, Martin AC, Richards J, Mott SL, Gellhaus PT et al (2022) Sequential intravesical gemcitabine and docetaxel for Bacillus Calmette-Gu\u00e9rin-Na\u00efve High-Risk Nonmuscle-Invasive bladder cancer. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000002740","journal-title":"J Urol"},{"key":"5613_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.31083\/j.fbl2908295","volume":"29","author":"MA Chakra","year":"2024","unstructured":"Chakra MA, Luo Y, Duquesne I, O\u2019Donnell MA (2024) Update on the mechanism of action of intravesical BCG therapy to treat Non-Muscle-Invasive bladder cancer. FBL 29:295. https:\/\/doi.org\/10.31083\/j.fbl2908295","journal-title":"FBL"},{"key":"5613_CR15","doi-asserted-by":"publisher","first-page":"69e17","DOI":"10.1016\/j.urolonc.2024.01.001","volume":"42","author":"A Porreca","year":"2024","unstructured":"Porreca A, Di Nicola M, Lucarelli G, Dorin VM, Soria F, Terracciano D et al (2024) Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: results from a machine learning-based analysis of a large multi-institutional database. Urologic Oncology: Seminars Original Investigations 42:69e17. https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.001","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"5613_CR16","doi-asserted-by":"publisher","first-page":"e223050","DOI":"10.1001\/jamanetworkopen.2022.3050","volume":"5","author":"KK Bree","year":"2022","unstructured":"Bree KK, Shan Y, Hensley PJ, Lobo N, Hu C, Tyler DS et al (2022) Management, surveillance patterns, and costs associated with Low-Grade papillary stage Ta Non\u2013Muscle-Invasive bladder cancer among older adults, 2004\u20132013. JAMA Netw Open 5:e223050. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.3050","journal-title":"JAMA Netw Open"},{"key":"5613_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","volume":"3","author":"AM Kamat","year":"2020","unstructured":"Kamat AM, Lerner SP, O\u2019Donnell M, Georgieva MV, Yang M, Inman BA et al (2020) Evidence-based assessment of current and emerging bladder-sparing therapies for Non\u2013muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy: A systematic review and Meta-analysis. Eur Urol Oncol 3:318\u2013340. https:\/\/doi.org\/10.1016\/j.euo.2020.02.006","journal-title":"Eur Urol Oncol"},{"key":"5613_CR18","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/jcm13144112","volume":"13","author":"R Passarelli","year":"2024","unstructured":"Passarelli R, Packiam VT (2024) Contemporary treatment of NMIBC\u2014Is it time to move on from BCG? J Clin Med 13:4112. https:\/\/doi.org\/10.3390\/jcm13144112","journal-title":"J Clin Med"},{"key":"5613_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009294.pub3","author":"MA Han","year":"2021","unstructured":"Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A et al (2021) Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Reviews. https:\/\/doi.org\/10.1002\/14651858.CD009294.pub3","journal-title":"Cochrane Database Syst Reviews"},{"key":"5613_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L et al (2010) Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. JCO 28:543\u2013548. https:\/\/doi.org\/10.1200\/JCO.2008.20.8199","journal-title":"JCO"},{"key":"5613_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","volume":"9","author":"M Kates","year":"2023","unstructured":"Kates M, Chu X, Hahn N, Pietzak E, Smith A, Shevrin DH et al (2023) Background and update for ECOG-ACRIN EA8212: A randomized phase 3 trial of intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-na\u00efve High-grade Non\u2013muscle-invasive bladder cancer (BRIDGE). Eur Urol Focus 9:561\u2013563. https:\/\/doi.org\/10.1016\/j.euf.2023.06.006","journal-title":"Eur Urol Focus"},{"key":"5613_CR22","doi-asserted-by":"publisher","unstructured":"Eraky A, Kolanukuduru KP, Hug B, Ben-David R, Attalla K, Waingankar N et al (2025) Differential response of low- and high-grade intermediate-risk nonmuscle-invasive bladder cancer to bacillus Calmette-Gu\u00e9rin and gemcitabine-docetaxel therapy. Urologic Oncology: Seminars and Original Investigations. https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.009","DOI":"10.1016\/j.urolonc.2025.03.009"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05613-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05613-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05613-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:54:10Z","timestamp":1767966850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05613-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5613"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05613-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}